---
source_pdf: "https://drive.google.com/file/d/1FtvdddKosDIeFPeMnqPk2-_p93yF6aVwDiQWynlLO14/view"
drive_folder: "Portfolio/Integral"
type: portfolio
company: Integral
ingested: 2025-12-23
original_filename: "network.bio + integral.gdoc"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1FtvdddKosDIeFPeMnqPk2-_p93yF6aVwDiQWynlLO14/view)

Raph

Asad

6-9 months of ideation

Pre-seed round + strategic

Business model innovation is what we have. Going outside of oncology

Direct to patient - not defensible

Assays for clinical care - not defensible

20M run-rate 2000 people vs.

Centralized ex-US - value prop to biobanks

Biobanks

Business model innovation

How do we get to biobanks without brute force???

Straightforward revenue share is not a viable solution. A lot of work to make data computable

What did UK Biobank get right?

Business model innovation

Put it in pot and see what scope of what

Sponsor R&D at your health system and extrenalize it

Tech transfer

Jumpstarting the marketplace

Senior folks that are starting off

3 Tier 3 biobanks (rural South Dakota + Texas)

Pre-defining the scope of exclusion / inclusion pharma

Sold to these folks in

CTO in mind

Seed growth

UK biobank has been formative

for reference: 4 pharma companies paid 200M pounds for access to the UKBB. this datset took 7 years to develop. ~500k patients.

send

Send message

1:23PM

Technology / product

Signaling

Health system level relationships

3rd - other strategic relationships

LabCorp

FMI -

Mayo

GC - intermountain

Gabe Otte

Providence

KP

Unity Point

Northwell

Tampa General

Foresite Labs

Gaurav